Tirzepatide 15mg
$134.99
Back to Products
≥98% Purity
Buy Tirzepatide 15mg
39-amino-acid synthetic peptide with C20 fatty diacid modification
$134.99 In Stock — Ships Same Week
Buy Now ≥98% Purity
HPLC Verified
Free Shipping
Orders $200+
30-Day Returns
Unopened Vials
Specifications
- Chemical
- 39-amino-acid synthetic peptide with C20 fatty diacid modification
- CAS Number
- 2023788-19-2
- Purity
- ≥98% HPLC verified
- Form
- Lyophilized powder
- SKU
- PG-1009
Tirzepatide 15mg Features
- Generic Mounjaro — same active compound at fraction of pharmacy price
- Dual GLP-1/GIP agonist — clinically proven Phase 3 weight reduction
- −22.5% body weight reduction at 15mg dose (SURMOUNT-1)
- Once-weekly dosing with 5-day half-life
- ≥98% HPLC verified purity, free US shipping over $200
Peer-Reviewed Research
References for Tirzepatide 15mg
The clinical and mechanistic claims on this page are drawn from the peer-reviewed literature listed below. Each citation links directly to the publisher or PubMed record.
- 1.Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).” New England Journal of Medicine, 2022. https://doi.org/10.1056/NEJMoa2206038
- 2.Aronne LJ, Horn DB, le Roux CW, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).” New England Journal of Medicine, 2025. https://doi.org/10.1056/NEJMoa2416394
- 3.Frías JP, Davies MJ, Rosenstock J, et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2).” New England Journal of Medicine, 2021. https://doi.org/10.1056/NEJMoa2107519
- 4.Rosenstock J, Wysham C, Frías JP, et al. “Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.” The Lancet, 2021. https://doi.org/10.1016/S0140-6736(21)01324-6
- 5.Heise T, Mari A, DeVries JH, et al. “Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes.” The Lancet Diabetes & Endocrinology, 2022. https://doi.org/10.1016/S2213-8587(22)00085-7
- 6.Malhotra A, Grunstein RR, Fietze I, et al. “Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA).” New England Journal of Medicine, 2024. https://doi.org/10.1056/NEJMoa2404881
- 7.Wilson JM, Nikooienejad A, Robins DA, et al. “The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.” Diabetes, Obesity and Metabolism, 2020. https://doi.org/10.1111/dom.14174
Research cited is published, peer-reviewed literature. Products sold for laboratory research use only. Not medical advice.
Related Peptides
Laboratory Use Only. This product is sold for in-vitro laboratory research. Not for human consumption, injection, or therapeutic application. Consult applicable regulations in your jurisdiction.